Cosmos Health Inc. reports developments across a vertically integrated healthcare platform that includes wholesale pharmaceutical distribution, contract manufacturing, proprietary nutraceutical brands and research and development. Recurring updates cover U.S. commercialization of the 18 Series nutraceutical portfolio, including Noor18, Liv18, Cur18 and Fort18, as well as Sky Premium Life orders, international distribution relationships and product launches.
Company news also covers financial results, margin and revenue drivers at Cana Laboratories, CosmoFarm and Decahedron, AI investments including the Cloudscreen drug-repurposing platform, and Nasdaq listing-compliance or governance matters tied to its common stock.
Cosmos Health (NASDAQ:COSM) announced that subsidiary Cana Laboratories signed a three-year contract manufacturing agreement with Verisfield.
Cana will produce 1.3 million units annually of VASCLOR GEST progesterone 400mg vaginal pessaries, totaling 3.9 million units, expanding its contract manufacturing customer base and capabilities in women's health and reproductive medicine.
Cosmos Health (NASDAQ:COSM) reported record FY2025 revenue of $65.3M, up 20% year-over-year, and an 83% gross profit increase to $7.9M with 12.1% margin. Q1 2026 revenue reached $17.9M, up 31%.
The company expects FY2026 revenue above $90M (~38% growth) and is targeting over $200M revenue and $44.2M adjusted EBITDA by 2029. Balance sheet metrics improved, non-core assets of about $20M were identified, and U.S. operations are underway with projected annualized revenue above $20M at roughly 75% gross margins within 12–18 months.
Cosmos Health (NASDAQ:COSM) announced that subsidiary Cana Laboratories has launched a state-of-the-art capsule production line and signed a new five-year contract manufacturing agreement with Provident Pharmaceuticals.
Cana will produce 385,000 units of CERTORUN (77,000 annually), supporting high-margin, recurring revenue and a diversified product portfolio, according to Cosmos Health.
Cosmos Health (NASDAQ:COSM) announced that subsidiary Cana Laboratories acquired international patent application WO2025108566A1 from Cloudpharm, enhancing its proprietary IP portfolio and product development pipeline.
Cana is pursuing national and regional patent protection and expanding nanotechnology-based platforms, leveraging its European GMP-licensed, EMA-certified manufacturing to develop pharmaceutical, nutraceutical, OTC, and specialized healthcare products, aligned with Cosmos Health’s vertical integration strategy.
Cosmos Health (NASDAQ:COSM) launched Oliv18 in the U.S., expanding its science-based 18 Series nutraceuticals into cardiovascular and antioxidant categories. Oliv18 is a USDA and EU organic-certified, 100% solvent-free whole olive polyphenol supplement sourced from Moroccan Saharan olive fruit and leaf.
A 250 mg daily dose, described as a clinically studied serving size, delivers about 11 teaspoons equivalent of extra virgin olive oil polyphenols and meets EFSA’s 5 mg/day hydroxytyrosol minimum for LDL oxidation protection. Oliv18 targets global cardiovascular and antioxidant markets projected to exceed $33 billion by 2035.
Cosmos Health (NASDAQ:COSM) announced that its Sky Premium Life nutraceutical and wellness brand is now available for shipment across all 27 EU Member States via leading e-commerce platform Skroutz.
96 products are listed, supporting broader European market penetration, brand visibility and, according to the company, revenue growth.
Cosmos Health (NASDAQ:COSM) is evaluating the monetization of approximately $20 million in non-core assets to enhance liquidity and support growth. Identified assets include about $15 million of independently valued real estate plus digital assets, marketable securities, and other liquid holdings, all described as not essential to core healthcare operations.
Real estate options under review include sale, sale-leaseback, or borrowing. The company indicates real estate value alone exceeds its current market capitalization and notes potential uses of proceeds such as funding a meaningful acquisition or achieving a net debt-free position.
Cosmos Health (NASDAQ:COSM) reported a stronger balance sheet and reaffirmed its growth outlook. Q1 2026 liabilities fell by $4.5 million (9.6%) quarter-over-quarter, while stockholders' equity rose 7.6% and the liabilities-to-assets ratio improved to 68.2%.
About 4.9 million Series B warrants expired unexercised, eliminating roughly 38% of warrant overhang with no dilution. The company is in discussions with the European Investment Bank for up to €25 million in R&D financing, holds real estate valued at about $15 million exceeding its market cap, and has a $300 million digital asset financing facility. FY2025 revenue reached a record $65.3 million, up 20% year-over-year, with Q1 2026 revenue of $17.9 million up 31%. Guidance through 2029 targets revenue of $200.6 million, gross margin of 35.5%, adjusted EBITDA of $44.2 million, cash of $62.9 million, and stockholders' equity of $92.3 million, with cash expected to exceed total debt by 2027. The company notes no known business reason for the recent share price decline.
Cosmos Health (NASDAQ:COSM) issued 2026–2029 guidance targeting strong growth and margin expansion. Revenue is projected to rise from $65.3M in 2025 to $200.6M in 2029 (32% CAGR), with gross profit increasing to $71.2M and gross margin to 35.5%.
Net income is projected to swing from a $19.1M loss in 2025 to $31.0M profit in 2029, with profitability expected in 2027. Adjusted EBITDA is guided to $44.2M by 2029, operating cash flow to $24.0M, cash to $62.9M, and stockholders’ equity to $92.3M, with all convertible notes anticipated to be repaid.
Cosmos Health (NASDAQ:COSM) announced that 4,874,126 Series B warrants, representing approximately 38% of its total outstanding warrants, expired unexercised at 5:00 p.m. New York City time on May 19, 2026.
The warrants had a $0.95 exercise price. Their expiration issues no new shares, causes no dilution, reduces warrant overhang, and simplifies the capital structure.